Sichuan Shuangma Expands CDMO Operations Into Major Western Markets, Secures Partnerships With Multiple US and European Biotech Firms

Deep News

昨天

On September 15, Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) published its investor relations activity record, highlighting a significant milestone.

According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1181425093"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181425093\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181425093?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181425093","market":"sh","top_or_hot":-1,"title":"Sichuan Shuangma Expands CDMO Operations Into Major Western Markets, Secures Partnerships With Multiple US and European Biotech Firms","media":"Deep News","content":"<p>On September 15, <b>Sichuan Hexie Shuangma Co., Ltd. (000935.SZ)</b> published its investor relations activity record, highlighting a significant milestone.<br><br>According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Shuangma Expands CDMO Operations Into Major Western Markets, Secures Partnerships With Multiple US and European Biotech Firms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Shuangma Expands CDMO Operations Into Major Western Markets, Secures Partnerships With Multiple US and European Biotech Firms\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time smaller\">2026-09-15 22:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On September 15, <b>Sichuan Hexie Shuangma Co., Ltd. (000935.SZ)</b> published its investor relations activity record, highlighting a significant milestone.<br><br>According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1181425093","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181425093","pubTimestamp":1789484132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On September 15, Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) published its investor relations activity record, highlighting a significant milestone.According to the filing, the company's CDMO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159837":"生物科技","BK4139":"生物科技","IEIH":"iShares Evolved U.S. Innovative Healthcare ETF","CDMO":"Avid Bioservices, Inc.","000935":"四川双马","AGNG":"Global X Aging Population ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","BK4588":"碎股","LNGR":"Global X Longevity Thematic ETF","BK0021":"外资并购(国际板)","BK0028":"国家队","GDOC":"Goldman Sachs Future Health Care Equity ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","XBI":"SPDR S&P Biotech ETF","BK0004":"股权转让","BK4581":"高盛持仓","SYNB":"PUTNAM BIOREVOLUTION ETF","BK0235":"非金矿物","BK4585":"ETF&股票定投概念"},"translate_title":"四川双马将CDMO业务拓展至西方主要市场，与多家美国和欧洲生物技术公司建立合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1,"MEDX":1,"IBBJ":1,"IEIH":1,"CDMO":1,"HBImain":1,"XBI":1,"LNGR":1,"000935":1,"SYNB":1,"AGNG":1,"GDOC":1},"content_text":"On September 15, Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) published its investor relations activity record, highlighting a significant milestone.According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}